Liu Chao, Liu Gang, Zhou Caixia, Ji Zhenguo, Zhen Yuzhi, Liu Kunshen
The First Hospital of Hebei Medical University, China.
Can J Cardiol. 2007 Sep;23(11):865-8. doi: 10.1016/s0828-282x(07)70840-1.
Refractory congestive heart failure (CHF) with diuretic resistance is life-threatening and predicts a short life expectancy. Glucocorticoids have been proven to have potent diuretic effects in animal studies; however, their efficacy in CHF patients with diuretic resistance is not known.
Thirteen CHF patients with significant volume overload and diuretic resistance who failed to respond to a conventional sequential nephron blockade therapeutic strategy; that is, the coadministration of a thiazide (hydrochlorothiazide) and spironolactone, in combination with loop diuretics, were studied. Prednisone (1 mg/kg daily) was then added to standard care, with other medications unchanged, to determine diuretic efficacy in these CHF patients. Variables included body weight, urine volume, serum electrolytes and renal function.
Adding prednisone resulted in striking diuresis with a mean (+/- SD) body weight reduction of 9.39+/-3.09 kg. Prednisone significantly decreased serum creatinine by 52.21+/-48.68 mumol/L and increased glomerular filtration rate by 33.63+/-15.87 mL/min/1.73 m(2) compared with baseline. All patients were discharged from hospital with improved clinical status and renal function, and 11 patients remained alive in the long term. The main side effect of prednisone appeared to be hyperglycemia in diabetic patients.
The present study demonstrated that prednisone can rapidly eliminate volume overload and improve clinical status and renal function in CHF patients with diuretic resistance. Further prospective randomized clinical studies are warranted to confirm its clinical efficacy.
难治性充血性心力衰竭(CHF)伴利尿剂抵抗危及生命,且预示预期寿命较短。糖皮质激素在动物研究中已被证明具有强大的利尿作用;然而,其在伴有利尿剂抵抗的CHF患者中的疗效尚不清楚。
对13例存在大量容量超负荷且对常规序贯肾单位阻滞治疗策略(即噻嗪类药物(氢氯噻嗪)与螺内酯联合使用,并与襻利尿剂合用)无反应的CHF患者进行了研究。然后在标准治疗基础上加用泼尼松(每日1mg/kg),其他药物不变,以确定这些CHF患者的利尿效果。观察指标包括体重、尿量、血清电解质和肾功能。
加用泼尼松后出现显著利尿,平均(±标准差)体重减轻9.39±3.09kg。与基线相比,泼尼松使血清肌酐显著降低52.21±48.68μmol/L,肾小球滤过率增加33.63±15.87mL/min/1.73m²。所有患者出院时临床状况和肾功能均有所改善,11例患者长期存活。泼尼松的主要副作用似乎是糖尿病患者出现高血糖。
本研究表明,泼尼松可迅速消除容量超负荷,改善伴有利尿剂抵抗的CHF患者的临床状况和肾功能。需要进一步进行前瞻性随机临床研究以证实其临床疗效。